The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | The value of immunotherapies at first relapse
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, briefly summarizes his presentation at COMy 2022 which focused on the value of immunotherapies at first relapse in multiple myeloma. Dr Richardson mentions the importance of improving outcomes in newly diagnosed patients and the promise of personalizing treatment approaches with novel immunotherapies to provide patients with the best options. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
